Abstract 221P
Background
The gold standard treatment for the non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guerin (BCG). the instillation of BCG induces an inflammatory response followed by cytokines upregulation and downregulation with a clinical outcome. In this we are targeting the IL1-alpha and TNF-alpha genes and study their genetic polymorphism to elucidate their role in BCG response and tumor recurrence in NMIBC patients.
Methods
The blood samples collected from histopathologically confirmed 224 NMIBC patients from August 2020 to December 2022. The 124 patients were grouped as BCG nonresponsive (BCG-NR) and 100 patients were grouped under BCG-responsive (BCG-R). The classification of group based on the BCG response followed by SWOG protocol. Recurrence/progression of tumor after 6 months consider for the BCG-NR followed by cystoscopy. In contrast patients with no sign of recurrence and progression after 12 months of BCG therapy consider as BCG-R. The DNA was isolated for the genotypic analysis of IL1A -889 C/T-(rs1800587) and TNFA-1031 T/C (rs1799964), in both groups using Taq-Man Probe-based real-time polymerase chain reactions.
Results
In this study, IL1A -889 C, and TNFA, 1031's C allele frequency, were significantly higher in BCG-NR (P <.05). The IL-1 alpha-889 C/T (CC/CT+TT) and TNFA -1031 T/C (TT/TC+CC) genotype expression were shown to be significantly associated with BCG-NR and tumour recurrence (CC/CT+TT; P=.025, TT/TC+CC; P =0.045) as compared to BCG-R in NMIBC.
Conclusions
The genetic polymorphism of the cytokines IL1A -889 C/T (rs1800587) and TNFA-1031 (rs1799964) T/C is significantly susceptible to the recurrence of tumor, BCG response and lead the way for early therapeutic response in NMIBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract